NASDAQ:FOMX Menlo Therapeutics Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Menlo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.99 0.00 (0.00 %) (As of 03/9/2020) Add Compare Share Today's Range$2.99Now: $2.99▼$2.9950-Day Range$2.99MA: $2.99▼$2.9952-Week Range$1.97Now: $2.99▼$4.84VolumeN/AAverage Volume518,350 shsMarket Capitalization$184.12 millionP/E RatioN/ADividend YieldN/ABeta1.66 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Menlo Therapeutics. Previous Next 2.4 Community Rank Outperform VotesMenlo Therapeutics has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMenlo Therapeutics has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentMenlo Therapeutics has received 51.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote “Outperform” if you believe FOMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMenlo Therapeutics does not currently pay a dividend.Dividend GrowthMenlo Therapeutics does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Menlo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Menlo Therapeutics is held by insiders.Percentage Held by Institutions46.46% of the stock of Menlo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Menlo Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Menlo Therapeutics is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Menlo Therapeutics is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMenlo Therapeutics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FOMX Previous Symbol CUSIPN/A CIK1606645 Webwww.foamix.com Phone972-8931-6233Employees80 Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.60 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.76Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-74,160,000.00 Net MarginsN/A Return on Equity-100.58% Return on Assets-81.39%Miscellaneous Outstanding Shares61,580,000Market Cap$184.12 million Next Earnings DateN/A OptionableOptionable Receive FOMX News and Ratings via Email Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter. Menlo Therapeutics (NASDAQ:FOMX) Frequently Asked Questions What stocks does MarketBeat like better than Menlo Therapeutics? Wall Street analysts have given Menlo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Menlo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc. (NASDAQ:FOMX) posted its quarterly earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.07. View Menlo Therapeutics' earnings history. Who are some of Menlo Therapeutics' key competitors? Some companies that are related to Menlo Therapeutics include Canopy Rivers (RIV), ChromaDex (CDXC), MediWound (MDWD), Natural Alternatives International (NAII), Charlie's (CHUC), Happiness Biotech Group (HAPP), Sundial Growers (SNDL), Mannatech (MTEX), Glucose Health (GLUC), FitLife Brands (FTLF), FSD Pharma (HUGE), Cyanotech (CYAN), True Drinks (TRUU), Nutra Pharma (NPHC) and Exactus (EXDI). View all competitors. What other stocks do shareholders of Menlo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), OPKO Health (OPK) and Pfizer (PFE). Who are Menlo Therapeutics' key executives? Menlo Therapeutics' management team includes the following people: Mr. David T. Domzalski, CEO & Director (Age 52)Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)Dr. Iain A. Stuart, Chief R&D Officer (Age 46) What is Menlo Therapeutics' stock symbol? Menlo Therapeutics trades on the NASDAQ under the ticker symbol "FOMX." What is Menlo Therapeutics' stock price today? One share of FOMX stock can currently be purchased for approximately $2.99. How big of a company is Menlo Therapeutics? Menlo Therapeutics has a market capitalization of $184.12 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Menlo Therapeutics employs 80 workers across the globe. What is Menlo Therapeutics' official website? The official website for Menlo Therapeutics is www.foamix.com. How can I contact Menlo Therapeutics? Menlo Therapeutics' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected] This page was last updated on 11/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
